Form 4: Elanco Director Receives Annual Equity Award

Elanco Animal Health Director Denise Scots-Knight was granted 10,314 deferred stock units as an annual equity award.

Summary

• Denise Scots-Knight, a Director of Elanco Animal Health Inc. (ELAN), received an annual equity award.
• The award consisted of 10,314 deferred stock units of common stock.
• The transaction occurred on November 28, 2025, with a price of $0 per unit, indicating a grant.
• This grant is part of the standard annual equity compensation for non-employee members of the Board of Directors.
• Following this transaction, Scots-Knight beneficially owns a total of 88,714 shares of Elanco common stock.

Sentiment

Score: 7

Explanation: The grant of deferred stock units to a director is a standard compensation practice, aligning the director's interests with shareholders. It's a positive event for the director's personal holdings and a routine operational item for the company.

Positives

• Director Denise Scots-Knight received an annual equity award of 10,314 deferred stock units, increasing her beneficial ownership in the company.
• The equity grant aligns the director's financial interests more closely with those of the company's shareholders.

Future Outlook

NA

Industry Context

This is a routine insider transaction related to director compensation and does not provide broader industry context or trends.

Related Party Transactions

• Grant of 10,314 deferred stock units to Denise Scots-Knight, a non-employee director, as part of her annual equity compensation, which is a standard related-party transaction for director remuneration.

Stakeholder Impact

• Shareholders: Experience minor dilution from the issuance of new shares, but benefit from increased alignment of director's interests with long-term company performance.
• Director: Benefits from increased personal equity stake and compensation.

Key Dates

Recommendation

This Form 4 reports a routine annual equity award to a non-employee director, which is a standard compensation practice and does not provide new information that would alter an investment recommendation for Elanco Animal Health Inc. The transaction aligns the director's interests with shareholders but is not a material event for stock valuation.

Keywords

Elanco, ELAN, Form 4, insider transaction, equity award, director compensation, stock grant, beneficial ownership